This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Journal: Neurocase 1-7 (2012)
Authors: F.S Bersani, N Girardi, L Sanna, L Mazzarini, C Santucci, G.D Kotzalidis, G Sani, P De Rossi, R.N Raccah, S.S Caltagirone, M Battipaglia, S Capezzuto, G Bersani, P Girardi
Bersani, F. S., Girardi, N., Sanna, L., Mazzarini, L., Santucci, C., Kotzalidis, G. D., & Girardi, P. (2013). Neurocase, 19(5), 451-457.
This case report examines the effect of Brainsway® Deep TMS (Deep Transcranial Magnetic Stimulation) H-coil stimulation in a patient with bipolar depression. The patient was provided with 20 daily consecutive Transcranial Magnetic Stimulation sessions, as well as one session every 2 weeks, over 3 months after the initial treatment. In this patient, symptoms were significantly alleviated and cognition was significantly enhanced following treatment. Moreover, these beneficial effects were evident for 6 months post treatment.